SCHEMBL4284826

SCHEMBL4284826

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2ccccc2)c1-c1cccs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
CDC7 O00311 1/20 0.44
LMNA P02545 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
IDO1 P14902 2/20 0.39
POLB P06746 2/20 0.38
ALDH1A1 P00352 6/20 0.37
KDM4E B2RXH2 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 2/20 0.37
SLC9A1 P19634 1/20 0.37
GRM2 Q14416 1/20 0.37
HTT P42858 2/20 0.37
HPGD P15428 2/20 0.37
USP2 O75604 1/20 0.37
GLA P06280 1/20 0.37
ATM Q13315 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669940 0.83 CYP19A1 (0.48) CDC7TSHRIDO1POLBALDH1A1
SCHEMBL4292554 0.79 CDC7 (0.44) CDC7IDO1POLBSMN1; SMN2SLC9A1
SCHEMBL4295553 0.78 CDC7 (0.46) CDC7TP53IDO1SLC9A1GRM2
SCHEMBL4292592 0.78 GRM2 (0.41) KMT2ACDC7LMNATSHRIDO1
SCHEMBL4291497 0.76 GRM2 (0.39) KMT2ACDC7LMNAIDO1POLB
SCHEMBL3667322 0.73 ROCK2 (0.43) CDC7IDO1ALDH1A1KDM4ESLC9A1
SCHEMBL28340574 0.73 CDC7 (0.64) KMT2ACDC7LMNATSHRTP53
SCHEMBL3671620 0.72 CDC7 (0.39) CDC7IDO1POLBSMN1; SMN2SLC9A1
SCHEMBL3670826 0.72 CDC7 (0.41) CDC7TP53IDO1GRM2CYP19A1
SCHEMBL4291234 0.70 SMN1; SMN2 (0.51) KMT2ATSHRPOLBALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 KMT2A 1399/4885CDC7 8/4885LMNA 3167/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 KMT2A 1399/4885CDC7 8/4885LMNA 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.